Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Enterprise Value: 2009-2025

Historic Enterprise Value for Northwest Biotherapeutics (NWBO) over the last 17 years, with Sep 2025 value amounting to $351.2 million.

  • Northwest Biotherapeutics' Enterprise Value fell 11.42% to $351.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $341.9 million, marking a year-over-year decrease of 12.10%. This contributed to the annual value of $348.1 million for FY2024, which is 56.85% down from last year.
  • Per Northwest Biotherapeutics' latest filing, its Enterprise Value stood at $351.2 million for Q3 2025, which was up 3.07% from $340.7 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Enterprise Value ranged from a high of $1.2 billion in Q2 2021 and a low of $317.1 million during Q1 2025.
  • For the 3-year period, Northwest Biotherapeutics' Enterprise Value averaged around $544.0 million, with its median value being $514.2 million (2024).
  • As far as peak fluctuations go, Northwest Biotherapeutics' Enterprise Value skyrocketed by 1,110.62% in 2021, and later tumbled by 60.90% in 2024.
  • Northwest Biotherapeutics' Enterprise Value (Quarterly) stood at $634.3 million in 2021, then grew by 29.04% to $818.5 million in 2022, then declined by 1.44% to $806.7 million in 2023, then crashed by 56.85% to $348.1 million in 2024, then decreased by 11.42% to $351.2 million in 2025.
  • Its Enterprise Value stands at $351.2 million for Q3 2025, versus $340.7 million for Q2 2025 and $317.1 million for Q1 2025.